<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094897</url>
  </required_header>
  <id_info>
    <org_study_id>Wuxi4PH</org_study_id>
    <nct_id>NCT03094897</nct_id>
  </id_info>
  <brief_title>Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics</brief_title>
  <official_title>Phase 1 Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuxi No. 4 People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective
      for cancer diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observe radiation dose to healthy volunteers and patients; the correlation between integrin
      level and tumor/metastases uptake.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value of 18F-Al-NOTA-MATBBN in malignant lesions</measure>
    <time_frame>1 day</time_frame>
    <description>The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in malignant lesions will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events within 1 week after the injection and scanning of patients and patients will be followed and assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>18F-Al-NOTA-MATBBN PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imaging with 18F-Al-NOTA-MATBBN PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Al-NOTA-MATBBN PET/CT</intervention_name>
    <description>18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.</description>
    <arm_group_label>18F-Al-NOTA-MATBBN PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Imaging with 18F-Al-NOTA-MATBBN PET/CT.</description>
    <arm_group_label>18F-Al-NOTA-MATBBN PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteers or patients with age more than 18 yeas;

          2. The patients have been diagnosed with cancer or suspected with cancer;

          3. It must fulfill the ethical requirements and subjects have signed an informed consent.

        Exclusion Criteria:

          1. Pregnancy or nursing mothers;

          2. Having drugs or alcohol dependence;

          3. Hypersensitive to the active or inactive ingredients of the study drug;

          4. Having attended other drug clinical trials within three months;

          5. Cardiac functional insufficiency;

          6. Hepatic and renal function insufficiency;

          7. Hypertensive patients with serious complications;

          8. Endangering the safety of life.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chunjing Yu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chunjing Yu, PhD,MD</last_name>
    <phone>0510-88682783</phone>
    <email>ycj_wxd1978@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>min Yang, PhD</last_name>
    <phone>0510-88682783</phone>
    <email>ymzfk@163.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med. 2011 Feb;52(2):270-8. doi: 10.2967/jnumed.110.081620. Epub 2011 Jan 13.</citation>
    <PMID>21233180</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasms,Prostatic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

